Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Proton Therapy + Capecitabine in Pancreatic Cancer
NCT00438256Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2007
- Primary completion
- Dec 2017
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of capecitabine in pancreatic cancer (PC) (4 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Dose Limiting Toxicities at 3 weeks and Grade 3 or Greater Toxicity at 6 months. Started Dec 2007; status: completed.
02
Drugs
capecitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00438256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00438256.